Identification of an E3 ligase for CCTα. (A and B) CCTα was immunoprecipitated using 2 μg of CCTα antibody from 100 μg of MLE cell lysates and processed for CCT, β-actin, CaM, Skp1, and 14-3-3 immunoblotting (A), and bands were quantitated (B). (C) Cartoon illustrating a classic model of the SCF-E3 ligase complex substrate engagement. (D to F) Two micrograms of each plasmid encoding two F-box proteins was transfected into cells (1 × 106) by nucleofection. Twenty-four hours later, cells were lysed and assayed for CCT activity (D), immunoblotting (E), or phosphatidylcholine synthesis (F). (G to I) Cells (1 × 106) were transfected with 0.2 nmol of scrambled (CON) RNA, FBXL2 siRNA, or FBXW1 siRNA by nucleofection. Forty-eight hours later, cells were lysed and processed for CCT activity (G), immunoblotting (H), and phosphatidylcholine synthesis (I). (J) Cells were treated either with vehicle, PA103 (MOI, 10; 1 h), or A23187 (10 nM) for 4 h. Cells were lysed, and 10 μg of lysate was resolved by SDS-PAGE prior to FBXL2 or CCTα immunoblotting (upper panel). FBXL2 was immunoprecipitated in 200 μg of lysate and processed for CCTα or FBXL2 immunoblotting (lower panel). (K) Cells were transfected with either empty vector or FBXL2 plasmid and lysed; 10 μg of lysate was resolved by SDS-PAGE prior to CCTα immunoblotting (upper panel). CCTα was immunoprecipitated in 200 μg of lysate and processed for ubiquitin immunoblotting (lowest panel). (L) Cells (1 × 106) were transfected with 2 μg of FBXL2 and treated with vehicle, the lysosomal inhibitors leupeptin (1:1,000 dilution) or NH4Cl (10 mM), or the proteasomal inhibitor lactacystin (1:1,000 dilution). Twenty-four hours later, cells were lysed, and assays of CCT activity (upper) and CCTα mass (lower) were performed.